SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LCTX reported third quarter 2026 results. The price and volatility reaction is pending.
LCTXearnings

Earnings reactions, page 3

Lineage Cell Therapeutics, Inc. (LCTX) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenues for the three months ended September 30, 2026 were approximately $1.5 million.
  • Total operating expenses for the three months ended September 30, 2026 were approximately $8.8 million.
  • Loss from operations for the three months ended September 30, 2026 was $7.3 million.
  • Net income attributable to Lineage for the three months ended September 30, 2026 was $4.2 million.
  • Basic net income per common share attributable to Lineage was $0.02 for the three months ended September 30, 2026.
  • Cash, cash equivalents, and marketable securities were $45.2 million as of September 30, 2026.

Guidance

  • Cash, cash equivalents, and marketable securities as of September 30, 2026, expected to support planned operations into Q2 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →